# Efficacy and Safety of CRT, Durvalumab and Surgery for SST

> **NCT04465968** · PHASE3 · NOT_YET_RECRUITING · sponsor: **National Cancer Center Hospital East** · enrollment: 84 (estimated)

## Conditions studied

- Superior Sulcus Tumor
- Non-small Cell Lung Cancer Stage IIB
- Non Small Cell Lung Cancer Stage III

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** S1
- **RADIATION:** concurrent radiotherapy
- **DRUG:** Durvalumab
- **PROCEDURE:** Surgery
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04465968
- **Lead sponsor:** National Cancer Center Hospital East
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2020-09-01
- **Primary completion:** 2027-08-31
- **Final completion:** 2030-08-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2020-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04465968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04465968, "Efficacy and Safety of CRT, Durvalumab and Surgery for SST". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04465968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*